Clinical trial
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
Active, not recruiting · Phase 3 · 5 countries · Registry ID NCT06948435
Active, not recruitingPhase 3Interventional
What this study is about
GZL1 is an independent study conducted under the GZPL master protocol. GZL1 will evaluate the efficacy and safety of orforglipron for treatment of hypertension in participants with obesity or overweight.
A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.
Basic eligibility
Age18 Years to Not listed
SexAll
Healthy volunteersNot accepted
ConditionHypertension, Overweight or Obesity
Full registry criteria
Inclusion Criteria: * refer to the GZPL master protocol for screening eligibility. Exclusion Criteria: * refer to the GZPL master protocol for screening eligibility.
Treatments and study arms
Orforglipron
Drug
Administered orally
Placebo
Drug
placebo administered.
Primary outcomes
Change from Baseline in office Systolic Blood Pressure (SBP)Baseline to Week 36
Study locations
99 locations were listed when this page was built. The first 40 are shown.
CEMEDIC🇦🇷 Buenos Aires, Argentina
CIPREC🇦🇷 Buenos Aires, Argentina
CIPREC🇦🇷 Buenos Aires, Argentina
Instituto Médico Especializado (IME)🇦🇷 Buenos Aires, Argentina
Instituto de Investigaciones Clínicas Córdoba🇦🇷 Córdoba, Argentina
Centro de Investigaciones Clínicas Baigorria🇦🇷 Granadero Baigorria, Argentina
INECO Neurociencias Oroño🇦🇷 Rosario, Argentina
Instituto Médico Fundación Grupo Colaborativo Rosario Investigación y Prevención Medica🇦🇷 Rosario, Argentina
Santa Maria de la Salud Centro Medico🇦🇷 San Isidro, Argentina
Beijing Pinggu District Hospital🇨🇳 Beijing, China
China-Japan Union Hospital🇨🇳 Changchun, China
Changde First People's Hospital🇨🇳 Changde, China
Sichuan Provincial People's Hospital🇨🇳 Chengdu, China
The Second Affiliated Hospital of Chongqing Medical University - Yuzhong Campus🇨🇳 Chongqing, China
Jinan Central Hospital🇨🇳 Jinan, China
Lishui Central Hospital🇨🇳 Lishui, China
The First Affiliated Hospital of Henan University of Science &Technology🇨🇳 Luoyang Shi, China
Ruijin Hospital Shanghai Jiaotong University School of Medicine🇨🇳 Shanghai, China
Siping Central People's Hospital🇨🇳 Siping, China
Wuxi People's Hospital🇨🇳 Wuxi, China
Shaanxi provincial people's hospital🇨🇳 Xi'an, China
Ordinace Rihackovi, s.r.o.🇨🇿 Brno, Czechia
Top Moravia Health🇨🇿 Brno, Czechia
CTC Hodonin s.r.o.🇨🇿 Hodonín, Czechia
MUDr. Sarka Drinkova🇨🇿 Ledeč nad Sázavou, Czechia
CCR Ostrava s.r.o🇨🇿 Ostrava, Czechia
Diahelp s.r.o🇨🇿 Pardubice V, Czechia
Angiocentrum Komorany🇨🇿 Prague, Czechia
Clinoxus🇨🇿 Prague, Czechia
Praglandia s.r.o🇨🇿 Prague, Czechia
Zentrum für klinische Studien Bad Homburg🇩🇪 Bad Homburg, Germany
FutureMeds GmbH🇩🇪 Berlin, Germany
Zentrum fur klinische Forschung - Köln🇩🇪 Cologne, Germany
Hausärztlich-Kardiologisches MVZ am Felsenkeller GmbH/Zentrum für klinische Studien🇩🇪 Dresden, Germany
Universitaetsklinikum Carl Gustav Carus Dresden🇩🇪 Dresden, Germany
Medizentrum Essen Borbeck🇩🇪 Essen, Germany
AmBeNet GmbH🇩🇪 Leipzig, Germany
Familienmedizinisches Zentrum Radowsky🇩🇪 Leipzig, Germany
RED-Institut GmbH🇩🇪 Oldenburg, Germany
Athens Medical Center - Psychikon branch🇬🇷 Athens, Greece